158 related articles for article (PubMed ID: 38807378)
1. Exploring the interplay between triple-negative breast cancer stem cells and tumor microenvironment for effective therapeutic strategies.
Zou Z; Luo T; Wang X; Wang B; Li Q
J Cell Physiol; 2024 May; ():. PubMed ID: 38807378
[TBL] [Abstract][Full Text] [Related]
2. The Tumor Microenvironment as a Driving Force of Breast Cancer Stem Cell Plasticity.
Fico F; Santamaria-Martínez A
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33371274
[TBL] [Abstract][Full Text] [Related]
3. Role of cancer stem cell ecosystem on breast cancer metastasis and related mouse models.
Peng X; Dong H; Zhang L; Liu S
Zool Res; 2024 May; 45(3):506-517. PubMed ID: 38682432
[TBL] [Abstract][Full Text] [Related]
4. Breast Cancer Stem-Like Cells in Drug Resistance: A Review of Mechanisms and Novel Therapeutic Strategies to Overcome Drug Resistance.
Saha T; Lukong KE
Front Oncol; 2022; 12():856974. PubMed ID: 35392236
[TBL] [Abstract][Full Text] [Related]
5. The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer.
He L; Wick N; Germans SK; Peng Y
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944829
[TBL] [Abstract][Full Text] [Related]
6. Cancer stem cell-derived CHI3L1 activates the MAF/CTLA4 signaling pathway to promote immune escape in triple-negative breast cancer.
Ji S; Yu H; Zhou D; Fan X; Duan Y; Tan Y; Lang M; Shao G
J Transl Med; 2023 Oct; 21(1):721. PubMed ID: 37838657
[TBL] [Abstract][Full Text] [Related]
7. Targeting triple negative breast cancer stem cells using nanocarriers.
Dasari N; Guntuku GS; Pindiprolu SKSS
Discov Nano; 2024 Mar; 19(1):41. PubMed ID: 38453756
[TBL] [Abstract][Full Text] [Related]
8. Breast Cancer Stem Cells: Signaling Pathways, Cellular Interactions, and Therapeutic Implications.
Wang L; Jin Z; Master RP; Maharjan CK; Carelock ME; Reccoppa TBA; Kim MC; Kolb R; Zhang W
Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805056
[TBL] [Abstract][Full Text] [Related]
9. Targeting Triple Negative Breast Cancer Stem Cells by Heat Shock Protein 70 Inhibitors.
Tsai CH; Weng JR; Lin HW; Lu MT; Liu YC; Chu PC
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230821
[TBL] [Abstract][Full Text] [Related]
10. Cytokines, breast cancer stem cells (BCSCs) and chemoresistance.
Chen W; Qin Y; Liu S
Clin Transl Med; 2018 Sep; 7(1):27. PubMed ID: 30175384
[TBL] [Abstract][Full Text] [Related]
11. Tumor Necrosis Factor-α (TNFα) Stimulate Triple-Negative Breast Cancer Stem Cells to Promote Intratumoral Invasion and Neovasculogenesis in the Liver of a Xenograft Model.
Narasimhan H; Ferraro F; Bleilevens A; Weiskirchen R; Stickeler E; Maurer J
Biology (Basel); 2022 Oct; 11(10):. PubMed ID: 36290384
[TBL] [Abstract][Full Text] [Related]
12. Upregulated SCUBE2 expression in breast cancer stem cells enhances triple negative breast cancer aggression through modulation of notch signaling and epithelial-to-mesenchymal transition.
Chen JH; Kuo KT; Bamodu OA; Lin YC; Yang RB; Yeh CT; Chao TY
Exp Cell Res; 2018 Sep; 370(2):444-453. PubMed ID: 29981340
[TBL] [Abstract][Full Text] [Related]
13. FBXL2 promotes E47 protein instability to inhibit breast cancer stemness and paclitaxel resistance.
Li F; Niu M; Qin K; Guo R; Yi Y; Xu J; Li L; Xie S; Fu M; Wen N; Liao W; Xiao ZJ
Oncogene; 2023 Jan; 42(5):339-350. PubMed ID: 36460773
[TBL] [Abstract][Full Text] [Related]
14. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2
Ly S; Anand V; El-Dana F; Nguyen K; Cai Y; Cai S; Piwnica-Worms H; Tripathy D; Sahin AA; Andreeff M; Battula VL
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722905
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Rubinstein-Achiasaf L; Morein D; Wiemann S; Körner C; Ben-Baruch A
Front Immunol; 2019; 10():757. PubMed ID: 31031757
[TBL] [Abstract][Full Text] [Related]
16. Ethnic disparities in the immune microenvironment of triple negative breast cancer and its role in therapeutic outcomes.
Zajac KK; Malla S; Babu RJ; Raman D; Tiwari AK
Cancer Rep (Hoboken); 2023 Sep; 6 Suppl 1(Suppl 1):e1779. PubMed ID: 36632988
[TBL] [Abstract][Full Text] [Related]
17. Elimination of epithelial-like and mesenchymal-like breast cancer stem cells to inhibit metastasis following nanoparticle-mediated photothermal therapy.
Paholak HJ; Stevers NO; Chen H; Burnett JP; He M; Korkaya H; McDermott SP; Deol Y; Clouthier SG; Luther T; Li Q; Wicha MS; Sun D
Biomaterials; 2016 Oct; 104():145-57. PubMed ID: 27450902
[TBL] [Abstract][Full Text] [Related]
18. Targeting Cancer Stem Cells in Triple-Negative Breast Cancer.
Park SY; Choi JH; Nam JS
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31324052
[TBL] [Abstract][Full Text] [Related]
19. Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer.
Shao C; Anand V; Andreeff M; Battula VL
Ann N Y Acad Sci; 2022 Feb; 1508(1):35-53. PubMed ID: 34596246
[TBL] [Abstract][Full Text] [Related]
20. Targeting Breast Cancer Stem Cells.
Zhang L; Chen W; Liu S; Chen C
Int J Biol Sci; 2023; 19(2):552-570. PubMed ID: 36632469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
